Stockscreener 앱 받기
4.62
0.22%
-0.010
Sagimet Biosciences Inc 주식(SGMT)의 최신 뉴스
Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results - Insider Monkey
Top 10 Stocks Under $5 That Could Triple - Insider Monkey
Aug Rallies: How does Sagimet Biosciences Inc score in quality rankingsRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - MSN
If You Invested $1,000 in Sagimet Biosciences Inc. (SGMT) - Stock Titan
Sagimet rises after denifanstat succeeds in late stage trial - MSN
Total debt per share of Sagimet Biosciences Inc. Class A – DUS:0O2 - TradingView
HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Q1 Earnings Forecast for SGMT Issued By HC Wainwright - MarketBeat
Citizens reiterates Sagimet Biosciences stock rating on MASH progress - Investing.com UK
Citizens reiterates Sagimet Biosciences stock rating on MASH progress By Investing.com - Investing.com Nigeria
Sagimet: Advancing FASN Inhibitor Pipeline and Solid Cash Position Support Buy Rating and $26 Target - TipRanks
Sagimet: Underappreciated, De-Risked Pipeline with Near-Term Milestones Supports Buy Rating - TipRanks
Sagimet Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oppenheimer reiterates Sagimet stock rating on MASH trial progress By Investing.com - Investing.com India
Oppenheimer reiterates Sagimet stock rating on MASH trial progress - Investing.com
Sagimet Biosciences Reports 2025 Financial Results, Advances MASH and Acne Clinical Programs with Denifanstat and Resmetirom Combination 14 - Minichart
Sagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC Wainwright - MarketBeat
Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating - TipRanks
Sagimet Biosciences Advances FASN Inhibitor Pipeline with Positive Phase 3 Results for Denifanstat in Acne and MASH Clinical Trials - Minichart
Sagimet Biosciences (NASDAQ:SGMT) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress - TipRanks
MASH and acne trial gains highlight Sagimet (NASDAQ: SGMT) 2025 update - Stock Titan
Sagimet Biosciences Q4 net loss narrows as R&D expenses fall - TradingView
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - The Manila Times
SGMT: Positive clinical progress in MASH and acne, with $113.1M cash and $51.0M net loss in 2025 - TradingView
Sagimet 10-K: Net Loss $51.0M, EPS $(1.58) - TradingView
Acne drug filing in China, new liver trial planned by Sagimet - Stock Titan
Sagimet Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday - MarketBeat
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. - Defense World
Bull Bear: How does Sagimet Biosciences Inc score in quality rankings2025 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn
SGMT Should I Buy - Intellectia AI
SGMT: Lead FASN inhibitor advances in MASH and acne, with pivotal trials and regulatory milestones ahead - TradingView
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - The Manila Times
Sagimet Biosciences to Participate in Upcoming Investor Conferences in March 2026 - Quiver Quantitative
Biotech Sagimet lines up three March investor conferences - Stock Titan
SGMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SGMTSagimet Biosciences Inc. Latest Stock News & Market Updates - Stock Titan
Sagimet (NASDAQ: SGMT) CMO receives 88,000-share option and 44,000 RSUs - Stock Titan
Sagimet Biosciences (SGMT) CFO awarded 88,000 options and 44,000 RSUs - Stock Titan
What is the long term forecast for Sagimet Biosciences Inc. stockChart Signals & Short-Term Swing Trade Alerts - mfd.ru
Can Sagimet Biosciences Inc. continue delivering strong returnsTrade Volume Report & Smart Money Movement Alerts - mfd.ru
Sagimet (SGMT) CEO granted 256k options and 128k RSUs in Form 4 - Stock Titan
Growth Value: Is Sagimet Biosciences Inc in a consolidation phaseJuly 2025 Retail & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Sagimet Biosciences (NASDAQ:SGMT) vs. AC Immune (NASDAQ:ACIU) Financial Survey - Defense World
Don't Ignore The Insider Selling In Sagimet Biosciences - simplywall.st
Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference - MarketBeat
1.82%
자본화:
|
볼륨(24시간):